Intracellular codelivery of anti-inflammatory drug and anti-miR 155 to treat inflammatory disease

• DOI: 10.1016/j.apsb.2020.06.005
• Publication Date: 2020-06-16T00:40:44Z
• Authors: Chao Teng; Chenshi Lin; Feifei Huang; Xuyang Xing; Shenyu Chen; Ling Ye; Helena S. Azevedo; Chenjie Xu; Zhengfeng Wu; Zhongjian Chen; Wei He
• Keywords: Baicalein

Atherosclerosis (AS) is a lipid-driven chronic inflammatory disease occurring at the arterial subendothelial space. Macrophages play critical role in initiation and development of AS. Herein, targeted codelivery anti-miR 155 anti-inflammatory baicalein exploited to polarize macrophages toward M2 phenotype, inhibit inflammation treat The system consists carrier-free strategy (drug-delivering-drug, DDD), fabricated by loading anti-miR155 on nanocrystals, named as nanorods (BNRs), followed sialic acid coating target macrophages. system, with diameter 150 nm, enables efficient intracellular delivery polarizes M1 M2, while markedly lowers level factors vitro vivo. In particular, fate assay reveals that allows for sustained drug release over time after internalization. Moreover, due prolonged blood circulation improved accumulation AS plaque, significantly alleviates animal model increasing artery lumen diameter, reducing pressure, promoting polarization, inhibiting secretion decreasing lipids. Taken together, could potentially be used vascular inflammation.